Breadth of presentations, including one oral and two flash talks, showcase Blueprint Medicines' leadership role in advancing care for patients with systemic mastocytosis CAMBRIDGE, Mass. , June 12, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced data presentations reflecting over a decade of collaboration with clinical experts and patient advocates to transform the treatment of systemic... Read More

Adds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the Sanofi portfolio PARIS and CAMBRIDGE, Mass. , June 2, 2025 /PRNewswire/ -- Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis (SM), a rare immunological disease, and other KIT-driven diseases, have entered into an agreement under... Read More

Achieved 61% year-over-year growth with $149.4 million in AYVAKIT net product revenues in the first quarter 2025 Raising AYVAKIT net product revenue guidance to $700 - $720 million for 2025 Initiated BLU-808 proof of concept studies in allergic rhinoconjunctivitis and chronic urticaria CAMBRIDGE, Mass. , May 1, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today reported financial results, provided a... Read More

CAMBRIDGE, Mass. , April 25, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday , May 1, 2025, to report its first quarter 2025 financial results and provide a corporate update. To access the live conference call, please dial 833-470-1428 (domestic) or 404-975-4839 (international) and refer to conference ID... Read More

CAMBRIDGE, Mass. , March 31, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that company management will participate virtually in a fireside chat at the 24 th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025 , at 12:45 p.m. ET . A live webcast of the presentation will be available by visiting the Investors & Media section of Blueprint Medicines' website at... Read More

Updated data show AYVAKIT® (avapritinib) was safe and effective for long-term treatment of ISM, with sustained symptom and quality-of-life benefit and no new safety signals with multiple years of therapy AYVAKIT-treated patients achieved improvements in bone health based on an analysis of bone mineral density scans, underscoring the importance of treating patients early in the ISM disease course BLU-808 healthy volunteer... Read More

Achieved $479.0 million in AYVAKIT® (avapritinib) global net product revenues in 2024, including $144.1 million in the fourth quarter Anticipate global AYVAKIT net product revenue of approximately $680 million to $710 million in 2025, representing 45% percent year-over-year growth at the midpoint Peak systemic mastocytosis franchise revenue opportunity updated to $4 billion, with AYVAKIT expected to achieve $2 billion in... Read More

CAMBRIDGE, Mass. , Feb. 5, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, February 13, 2025 , to report its fourth quarter and full year 2024 financial results and provide a corporate update. To access the live conference call, please dial 833-470-1428 (domestic) or 404-975-4839 (international) and refer to... Read More

Updating peak systemic mastocytosis franchise revenue opportunity to $4 billion , catalyzed by strong AYVAKIT® (avapritinib) launch and evolving SM prevalence estimates Expect to achieve $2 billion in AYVAKIT revenue by 2030 BLU-808 demonstrates wide therapeutic window with rapid, robust and sustained tryptase reductions exceeding 80% in Phase 1 healthy volunteer study Kate Haviland , CEO, to present at J.P. Morgan... Read More

CAMBRIDGE, Mass. , Dec. 18, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced that Kate Haviland , Chief Executive Officer, will present a corporate overview and 2025 outlook at the 43 rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 , at 9:00 a.m. PT ( 12:00 p.m. ET ). A live webcast of the presentation will be available by visiting the Investors & Media section of... Read More

ASH data reinforce survival benefits of front-line AYVAKIT® (avapritinib) use in patients with advanced SM Bone density analyses reported in patients with advanced SM underscore disease-modifying effects of AYVAKIT CAMBRIDGE, Mass. , Dec. 7, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced data presentations that continue to demonstrate the long-term clinical benefits of AYVAKIT®... Read More

Achieved $128.2 million in AYVAKIT net product revenues in the third quarter 2024 Raising AYVAKIT net product revenue guidance to $475 million to $480 million for 2024 On track to initiate the registration-enabling HARBOR Part 2 study of elenestinib in ISM by year end CAMBRIDGE, Mass. , Oct. 30, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today reported financial results, provided a business update... Read More

CAMBRIDGE, Mass. , Oct. 16, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, October 30, 2024 , to report its third quarter 2024 financial results and provide a corporate update. To access the live conference call, please dial 833-470-1428 (domestic) or 404-975-4839 (international) and refer to conference ID... Read More

CAMBRIDGE, Mass. , Sept. 10, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced its participation in the following upcoming virtual investor conferences: Stifel 2024 Immunology and Inflammation Virtual Summit on Tuesday, September 17, 2024 , at 2:00 p.m. ET . TD Cowen's Chronic Urticaria Summit on Friday, September 20, 2024 , at 11:00 a.m. ET . A live webcast of each presentation will be... Read More

Achieved $114.1 million in AYVAKIT net product revenues in the second quarter 2024 Raising AYVAKIT net product revenue guidance to $435 million to $450 million for 2024 Initiated Phase 1 healthy volunteer trial of wild-type KIT inhibitor BLU-808 CAMBRIDGE, Mass. , Aug. 1, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today reported financial results, provided a business update for the second quarter... Read More

CAMBRIDGE, Mass. , July 18, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 1, 2024 , to report its second quarter 2024 financial results and provide a corporate update. To access the live conference call, please dial 833-470-1428 (domestic) or 404-975-4839 (international) and refer to conference ID... Read More

Breadth of data across 7 presentations, including 4 oral, reflects continued leadership in advancing the understanding and treatment of systemic mastocytosis CAMBRIDGE, Mass. , May 30, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced multiple upcoming datasets across two key conferences that reinforce the significant real-world burden of systemic mastocytosis (SM), and highlight the durable... Read More

Updated Phase 1 dose escalation data show that BLU-222 in combination with ribociclib and fulvestrant was well-tolerated at clinically active dose levels with no dose-limiting toxicities Early signal of clinical activity includes compelling biomarker reductions correlated with BLU-222 exposure CAMBRIDGE, Mass. , May 23, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced updated data from the... Read More

CAMBRIDGE, Mass. , May 6, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective May 1, 2024 , the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 6,400 shares of its common stock and an aggregate of 3,200 restricted stock units (RSUs) to two new employees under Blueprint Medicines' 2020 Inducement... Read More

Achieved $92.5 million in AYVAKIT net product revenues in the first quarter 2024 Raising guidance to $390 million to $410 million in full year AYVAKIT net product revenues Strengthening presence in allergy and inflammation with the IND for wild-type KIT inhibitor BLU-808 on track for filing in Q2 CAMBRIDGE, Mass. , May 2, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today reported financial results,... Read More

CAMBRIDGE, Mass. , April 18, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday , May 2, 2024, to report its first quarter 2024 financial results and provide a corporate update. To access the live conference call, please dial 833-470-1428 (domestic) or 404-975-4839 (international) and refer to conference ID... Read More

­Dr. Mariana Castells , M.D., Ph.D., a renowned researcher and clinical expert in mast cell diseases, will join members of Blueprint Medicines' management team to provide a perspective on the mast cell as a promising target for treating allergic and inflammatory disease on April 25, 2024 , at 10:00 a.m. ET First in a series of planned webcasts hosted by Blueprint to highlight evolving science around R&D and pipeline strategy... Read More

CAMBRIDGE, Mass. , April 4, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective April 1, 2024 , the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 3,711 shares of its common stock and an aggregate of 1,854 restricted stock units (RSUs) to three new employees under Blueprint Medicines' 2020... Read More

CAMBRIDGE, Mass. , March 6, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective March 1, 2024 , the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 2,615 shares of its common stock and an aggregate of 1,307 restricted stock units (RSUs) to three new employees under Blueprint Medicines' 2020... Read More

AYVAKIT data in patients with indolent systemic mastocytosis show durable efficacy and favorable safety supporting long-term treatment, consistent with real-world experience observed in commercial setting Preclinical data for BLU-808, a highly selective and potent oral wild-type KIT inhibitor with best-in-class potential, supports development in chronic urticaria and other mast cell diseases; on track to submit IND to FDA in... Read More

Achieved $204.2 million in AYVAKIT ® /AYVAKYT ® (avapritinib) net product revenues in 2023, including $71.0 million in the fourth quarter Anticipate global AYVAKIT net product revenue of approximately $360 million to $390 million in 2024, representing >80 percent year-over-year growth at the midpoint Nine presentations highlighting AYVAKIT long-term safety and efficacy, BLU-808 preclinical profile, and additional data... Read More

CAMBRIDGE, Mass. , Feb. 5, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective February 1, 2024 , the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 1,717 shares of its common stock and an aggregate of 858 restricted stock units (RSUs) to three new employees under Blueprint Medicines' 2020... Read More

CAMBRIDGE, Mass. , Feb. 1, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, February 15, 2024 , to report its fourth quarter and full year 2023 financial results and provide a corporate update. To access the live conference call, please dial 833-470-1428 (domestic) or 404-975-4839 (international) and refer to... Read More

AYVAKIT ® (avapritinib) launch in indolent systemic mastocytosis to drive strong revenue growth in 2024, with ongoing U.S. launch and recent EU approval Expanding mast cell disease leadership with oral wild-type KIT inhibitor, BLU-808, advancing into clinical development; IND submission planned in Q2 2024 Maintaining durable cash position through focused investment and global commercial execution Kate Haviland , Chief... Read More

CAMBRIDGE, Mass. , Jan. 5, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective January 1, 2023 , the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 9,393 shares of its common stock and an aggregate of 4,696 restricted stock units (RSUs) to two new employees under Blueprint Medicines' 2020... Read More

CAMBRIDGE, Mass. , Dec. 18, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced that Kate Haviland , Chief Executive Officer, will present a corporate overview and 2024 outlook at the 42 nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 , at 10:30 a.m. PT ( 1:30 p.m. ET ). A live webcast of the presentation will be available by visiting the Investors & Media section of... Read More

In the European Union, patients with indolent systemic mastocytosis now have an approved medicine that treats the primary driver of disease Approval based on data from PIONEER trial, in which AYVAKYT achieved significant improvements across a broad range of symptoms with a safety profile comparable to placebo 1 CAMBRIDGE, Mass. , Dec. 12, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced the... Read More

HARBOR Part 1 trial data in indolent systemic mastocytosis showed elenestinib was well-tolerated with broad symptom improvement, supporting further development to expand and extend company's SM franchise leadership CAMBRIDGE, Mass. , Dec. 9, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced data showcasing its commitment to advance the scientific understanding and treatment of systemic... Read More

CAMBRIDGE, Mass. , Dec. 4, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective December 1, 2023 , the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 2,503 shares of its common stock and an aggregate of 1,251 restricted stock units (RSUs) to two new employees under Blueprint Medicines' 2020... Read More

CAMBRIDGE, Mass. , Nov. 28, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced that company management will participate virtually in a fireside chat at the JMP Securities Hematology and Oncology Summit on Tuesday, December 5, 2023 at 11:00 a.m. ET . A live webcast of the presentation will be available by visiting the Investors & Media section of Blueprint Medicines' website at... Read More

For the first time, the estimated 40,000 patients with indolent SM in the EU 1,2* would have a medicine that treats the primary disease driver 3,4 Opinion based on the positive PIONEER trial, in which once-daily AYVAKYT achieved significant improvements across a broad range of symptoms with a comparable safety profile to placebo 3,4 CAMBRIDGE, Mass. , Nov. 10, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq:... Read More

CAMBRIDGE, Mass. , Nov. 3, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective November 1, 2023 , the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 5,034 shares of its common stock and an aggregate of 2,517 restricted stock units (RSUs) to three new employees under Blueprint Medicines' 2020... Read More

Achieved $54.2 million in AYVAKIT®/AYVAKYT® (avapritinib) net product revenues, representing 90% growth year-over-year, and $56.6 million in total revenues in the third quarter of 2023 Approximately 800 patients on AYVAKIT in the U.S. at the end of the third quarter, more than 35% growth in treated patients quarter-over-quarter and driven by ISM Plan to present data from Part 1 of the HARBOR trial of elenestinib in ISM at... Read More

CAMBRIDGE, Mass. , Oct. 12, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, October 26, 2023 , to report its third quarter financial results and provide a corporate update. To access the live conference call, please dial 833-470-1428 (domestic) or 404-975-4839 (international), and refer to conference ID... Read More

CAMBRIDGE, Mass. , Oct. 5, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective October 1, 2023 , the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 3,655 shares of its common stock and an aggregate of 1,827 restricted stock units (RSUs) to four new employees under Blueprint Medicines' 2020... Read More

CAMBRIDGE, Mass. , Sept. 5, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective September 1, 2023 , the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 8,446 shares of its common stock and an aggregate of 4,221 restricted stock units (RSUs) to six new employees under Blueprint Medicines' 2020... Read More

CAMBRIDGE, Mass. , Aug. 4, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective August 1, 2023 , the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 2,669 shares of its common stock and an aggregate of 1,334 restricted stock units (RSUs) to five new employees under Blueprint Medicines' 2020... Read More

Achieved $39.9 million in AYVAKIT ® /AYVAKYT ® (avapritinib) net product revenues and $57.6 million in total revenues in the second quarter of 2023 AYVAKIT approved by the FDA for the treatment of adults with indolent systemic mastocytosis on May 22, 2023 Announced development candidate BLU-808, an oral, highly potent and selective wild-type KIT inhibitorb with first- and best-in-class potential, for the treatment of... Read More

CAMBRIDGE, Mass. , July 19, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, August 2, 2023 , to report its second quarter financial results and provide a corporate update. To access the live conference call, please dial 833-470-1428 (domestic) or 404-975-4839 (international), and refer to conference ID... Read More

CAMBRIDGE, Mass. , July 5, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective July 1, 2023 , the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 13,093 shares of its common stock and an aggregate of 6,546 restricted stock units (RSUs) to four new employees under Blueprint Medicines' 2020... Read More

CAMBRIDGE, Mass. , June 5, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective June 1, 2023 , the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 7,593 shares of its common stock and an aggregate of 3,796 restricted stock units (RSUs) to six new employees under Blueprint Medicines' 2020... Read More

Breadth of pipeline featured in multiple early clinical data presentations, reflecting diversity of fundamental growth drivers across development programs CAMBRIDGE, Mass. , June 3, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced clinical data for multiple programs across its precision therapy portfolio at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. The... Read More

First and only treatment approved by FDA for indolent SM CAMBRIDGE, Mass. , May 23 , 2023 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced that NEJM Evidence , a journal from The New England Journal of Medicine Group, has published detailed results from the PIONEER trial of AYVAKIT® (avapritinib) in patients with indolent systemic mastocytosis (ISM). Data reported in the publication show that... Read More

For the first time, patients with indolent SM have a medicine that treats the primary disease driver and is proven to provide broad and durable symptom relief -- Approval based on the positive PIONEER trial, in which once-daily AYVAKIT achieved significant improvements in disease symptoms and measures of mast cell burden, with a safety profile that compared favorably to placebo -- Blueprint Medicines to host investor... Read More

CAMBRIDGE, Mass. , May 4, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced that, effective May 1, 2023, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 18,300 shares of its common stock and an aggregate of 9,146 restricted stock units (RSUs) to eleven new employees under Blueprint Medicines' 2020... Read More

Achieved $39.1 million in AYVAKIT ® /AYVAKYT ® (avapritinib) net product revenues and $63.3 million in total revenues in the first quarter of 2023 Raising 2023 AYVAKIT net product revenue guidance to $135 million to $145 million for advanced SM and GIST, excluding additional revenue associated with anticipated U.S. FDA approval for indolent SM FDA target action date for AYVAKIT supplemental new drug application for indolent... Read More

CAMBRIDGE, Mass. , April 26, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the acceptance of clinical abstracts for multiple programs across its precision therapy portfolio at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, June 2 to 6 . The presentations showcase Blueprint Medicines' next wave of therapeutic candidates in its robust clinical pipeline, and highlight... Read More

CAMBRIDGE, Mass. , April 20, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday , May 4, 2023 to report its first quarter financial results and provide a corporate update. To access the live conference call, please dial 833-470-1428 (domestic) or 929-526-1599 (international), and refer to conference ID 668091. A... Read More

CAMBRIDGE, Mass. , April 11, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced its participation in the following upcoming investor conferences: 22 nd Annual Needham Healthcare Conference, held virtually, on Tuesday, April 18, 2023 at 2:15 p.m. ET . Stifel 2023 Targeted Oncology Days, held virtually, on Tuesday, April 25, 2023 at 11:30 a.m. ET . A live webcast of each presentation will be... Read More

CAMBRIDGE, Mass. , April 5, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that, effective April 1, 2023 , the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 5,933 shares of its common stock and an... Read More

CAMBRIDGE, Mass. , March 28, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the U.S. Food and Drug Administration (FDA) has lifted a partial clinical hold on the Phase 1/2 VELA trial of BLU-222. On February 10, 2023 , Blueprint Medicines announced the FDA placed a partial clinical hold on the VELA trial due to reported visual adverse events, consisting of transient, reversible... Read More

CAMBRIDGE, Mass. , March 7, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that, effective March 1, 2023 , the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 11,462 shares of its common stock and an... Read More

AYVAKIT achieved a statistically significant and clinically meaningful improvement in total symptom score that deepened over time, with improvements shown across all individual symptoms AYVAKIT achieved a statistically significant and clinically meaningful improvement on the Mastocytosis Quality of Life Questionnaire (MC-QoL) AYVAKIT had a favorable safety profile compared to placebo, supporting potential for chronic... Read More

CAMBRIDGE, Mass. , Feb. 23, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced it will regain global commercialization and development rights to GAVRETO® (pralsetinib), excluding Greater China , following a decision by Roche to discontinue the collaboration agreement between the companies for GAVRETO for strategic reasons. Under the terms of the agreement, the termination will be effective 12... Read More

Achieved $204.0 million in total revenues in 2022, including $111.0 million in AYVAKIT®/AYVAKYT® (avapritinib) net product revenues Continued progress toward regulatory approvals of AYVAKIT/AYVAKYT for indolent systemic mastocytosis, with FDA granting priority review of a supplemental new drug application and EMA validating a type II variation marketing authorization application Positive data from PIONEER trial of AYVAKIT in... Read More

CAMBRIDGE, Mass. , Feb. 10, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the U.S. Food and Drug Administration (FDA) verbally informed the company on February 8, 2023 that it has placed a partial clinical hold on the Phase 1/2 VELA trial of BLU-222 due to visual adverse events (AEs) observed in a limited number of patients. Patients currently enrolled in the trial are continuing on... Read More

CAMBRIDGE, Mass. , Feb. 9, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, February 16, 2023 to report its fourth quarter and full year 2022 financial results and provide a corporate update. To access the live conference call, please dial 844-200-6205 (domestic) or 929-526-1599 (international), and refer to... Read More

CAMBRIDGE, Mass. , Feb. 7, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that, effective February 1, 2023 , the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 36,260 shares of its common stock and... Read More

Significant scientific and clinical presence, including 10 presentations, underscores breadth and depth of SM leadership Blueprint Medicines to host investor conference call and webcast on Monday, February 27, 2023 CAMBRIDGE, Mass. , Feb. 3, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced plans to present detailed results from the registrational PIONEER trial of AYVAKIT® (avapritinib) in... Read More

FDA grants priority review and sets PDUFA action date of May 22, 2023 CAMBRIDGE, Mass. , Jan. 23, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental new drug application for AYVAKIT ® (avapritinib) for the treatment of adults with indolent systemic mastocytosis (SM). The FDA granted priority review with... Read More

CAMBRIDGE, Mass. , Jan. 6, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the appointment of John Tsai , M.D., to its board of directors. Dr. Tsai, who was President, Global Drug Development and Chief Medical Officer at Novartis AG from 2018 to 2022, brings more than 20 years of drug development and medical affairs experience in global pharmaceutical companies to Blueprint Medicines.... Read More

Expect to achieve high-end of 2022 total revenue guidance of $180 million to $200 million and AYVAKIT product revenue guidance of $108 million to $111 million Positioned for significant near-term growth with potential FDA approval of AYVAKIT® (avapritinib) in indolent systemic mastocytosis in the middle of 2023 Anticipate multiple clinical data catalysts across mast cell disorder, EGFR-mutant non-small cell lung cancer, and... Read More

CAMBRIDGE, Mass. , Jan. 4, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that, effective January 1, 2023 , the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 6,887 shares of its common stock and an... Read More

CAMBRIDGE, Mass. , Dec. 5, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that, effective December 1, 2022 , the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 23,604 shares of its common stock and... Read More

Company to present registrational PIONEER trial results at 2023 AAAAI Annual Meeting CAMBRIDGE, Mass. , Nov. 22, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the submission of a supplemental new drug application to the U.S. Food and Drug Administration (FDA) for AYVAKIT® (avapritinib) for the treatment of adults with indolent systemic mastocytosis (SM). AYVAKIT was designed to potently... Read More